Indication intelligence, analysis and sector perception

Intellia Therapeutics (NTLA) prices $100 million offering at $18.25

June 3, 2020

NTLA priced an offering of 5,479,453 shares of its common stock at a public offering price of $18.25 per share. Intellia also granted the underwriters a 30-day option to purchase up to an additional 821,917 shares The gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses have increased to $100 million from $75 million NTLA closed down -$0.66 to $20.26

RegMed/Cell and Gene Therapy Earnings Scorecard - Q1/20 - to date

May 30, 2020

A scorecard of 32 (added PSTI) earnings "confessions", 1 restatement and 1 acquisition of 35 covered  companies Added Mesoblast (MESO) and Precision (PGEN) The current LPS (loss per share) or net income, cash positions i.e. "runways"  is a reflection of this universe's investing "status"  

RegMed Investor (RMi) … Q1/2020 earnings reporting dates

May 26, 2020

Regenerative Medicine Earnings listing for Q1/20   My focus is to define the net income or loss, the per share amounts commonly an LPS (loss-per-share), cash positions (EOQ – “end-of-quarter”) and the “runway” of continuing operations.